Active Ingredient History
N,N’N’-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N’,N’’- triethylenephosphoramide (TEPA). The radiomimetic action of thiotepa is believed to occur through the release of ethylenimine radicals which, like irradiation, disrupt the bonds of DNA. One of the principal bond disruptions is initiated by alkylation of guanine at the N-7 position, which severs the linkage between the purine base and the sugar and liberates alkylated guanines. Thiotepa has been used in the palliation of a wide variety of neoplastic diseases. The more consistent results have been seen in: adenocarcinoma of the breast, adenocarcinoma of the ovary, superficial papillary carcinoma of the urinary bladder and for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Breast Neoplasms (approved 1959)
Ovarian Neoplasms (approved 1959)
Urinary Bladder Neoplasms (approved 1959)
Adrenoleukodystrophy (Phase 1/Phase 2)
Agammaglobulinemia (Phase 2)
Anemia (Phase 4)
Anemia, Aplastic (Phase 2)
Anemia, Diamond-Blackfan (Phase 1/Phase 2)
Anemia, Hemolytic (Phase 1/Phase 2)
Anemia, Refractory (Phase 2)
Anemia, Sickle Cell (Phase 2)
Arthritis, Juvenile (Phase 2)
Autoimmune Lymphoproliferative Syndrome (Phase 2)
beta-Thalassemia (Phase 1/Phase 2)
Bone Marrow Cells (Phase 2)
Bone Marrow Failure Disorders (Phase 1/Phase 2)
Brain Neoplasms (Phase 3)
Breast Neoplasms (Phase 3)
Breast Neoplasms, Male (Phase 2)
Burkitt Lymphoma (Phase 2)
Carcinoma, Embryonal (Phase 2)
Central Nervous System Diseases (Phase 2)
Central Nervous System Neoplasms (Phase 3)
Chediak-Higashi Syndrome (Phase 2/Phase 3)
Chordoma (Phase 1)
Choriocarcinoma (Phase 2)
Choroid Plexus Neoplasms (Phase 1)
Common Variable Immunodeficiency (Phase 2)
Congenital Bone Marrow Failure Syndromes (Phase 2)
Desmoplastic Small Round Cell Tumor (Phase 2)
DiGeorge Syndrome (Phase 2)
Drug Therapy (Phase 2)
Ependymoma (Phase 2/Phase 3)
Fallopian Tube Neoplasms (Phase 1/Phase 2)
Ganglioneuroblastoma (Phase 3)
Glioma (Phase 1)
Graft vs Host Disease (Phase 4)
Granulomatous Disease, Chronic (Phase 2)
Hair (Phase 2/Phase 3)
Hamartoma (Phase 1/Phase 2)
Head and Neck Neoplasms (Phase 2)
Hematologic Diseases (Phase 2/Phase 3)
Hematologic Neoplasms (Phase 2)
Hematopoietic Stem Cell Transplantation (Phase 2)
Hemoglobinopathies (Phase 1/Phase 2)
Hemoglobinuria, Paroxysmal (Phase 3)
Histiocytosis (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2/Phase 3)
HIV Infections (Phase 2)
Hodgkin Disease (Phase 2)
Hypertension, Pulmonary (Phase 2)
Idiopathic Pulmonary Fibrosis (Phase 1/Phase 2)
Immune System Diseases (Phase 2/Phase 3)
Immunoglobulin M (Phase 2)
Inflammation (Phase 2)
Inflammatory Breast Neoplasms (Phase 2)
Intestinal Neoplasms (Phase 2)
Intraocular Lymphoma (Phase 2)
Kidney Neoplasms (Phase 2)
Leukemia (Phase 4)
Leukemia, Biphenotypic, Acute (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Leukemia, Large Granular Lymphocytic (Phase 2)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia, Lymphoid (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Megakaryoblastic, Acute (Phase 2)
Leukemia, Monocytic, Acute (Phase 2)
Leukemia, Myeloid (Phase 2)
Leukemia, Myeloid, Acute (Phase 3)
Leukemia, Myeloid, Chronic-Phase (Phase 2)
Leukemia, Myelomonocytic, Chronic (Phase 2)
Leukemia, Myelomonocytic, Juvenile (Phase 3)
Liver Neoplasms (Phase 2)
Lung Diseases, Interstitial (Phase 2)
Lymphohistiocytosis, Hemophagocytic (Phase 2/Phase 3)
Lymphoma (Phase 4)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 2)
Lymphoma, Large-Cell, Immunoblastic (Phase 2/Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 2)
Lymphoproliferative Disorders (Phase 2/Phase 3)
Mannosidase Deficiency Diseases (Phase 1/Phase 2)
Medulloblastoma (Phase 4)
Metabolic Diseases (Phase 2)
Mucopolysaccharidosis I (Phase 1/Phase 2)
Multiple Myeloma (Phase 4)
Mycoses (Phase 2)
Myelodysplastic-Myeloproliferative Diseases (Phase 2/Phase 3)
Myelodysplastic Syndromes (Phase 4)
Myeloproliferative Disorders (Phase 2/Phase 3)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2/Phase 3)
Neoplasms, Germ Cell and Embryonal (Phase 4)
Neoplasms, Neuroepithelial (Early Phase 1)
Nerve Sheath Neoplasms (Phase 2)
Neuroblastoma (Phase 3)
Neuroectodermal Tumors (Phase 3)
Neuroectodermal Tumors, Primitive (Phase 2)
Neutropenia (Phase 1/Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 2)
Pediatrics (Phase 1)
Plasmacytoma (Phase 2)
Polycythemia Vera (Phase 2)
Primary Immunodeficiency Diseases (Phase 2)
Primary Myelofibrosis (Phase 2)
Pulmonary Disease, Chronic Obstructive (Phase 1/Phase 2)
Retinoblastoma (Phase 3)
Rhabdoid Tumor (Phase 3)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Sarcoma, Myeloid (Phase 2)
Scleroderma, Diffuse (Phase 2)
Scleroderma, Systemic (Phase 2)
Severe Combined Immunodeficiency (Phase 2)
Sezary Syndrome (Phase 2)
Stem Cell Transplantation (Phase 2)
Teratoma (Phase 2)
Testicular Neoplasms (Phase 2)
Thalassemia (Phase 1/Phase 2)
Thrombocythemia, Essential (Phase 2)
Thrombocytopenia (Phase 2)
Tissue Donors (Phase 2)
Transplantation (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Wiskott-Aldrich Syndrome (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
